Want to see TLPH full AI Analyst Report?
TLPH Stock Chart & Stats
$1.10
-$0.04(-6.10%)
At close: 4:00 PM EST
$1.10
-$0.04(-6.10%)
Day’s Range― - ―
52-Week Range$0.38 - $1.57
Previous CloseN/A
Volume42.81K
Average Volume (3M)2.97M
Market Cap
$64.87M
Enterprise Value$16.08M
Total Cash (Recent Filing)$21.11M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Aug 19, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding51,899,647
10 Day Avg. Volume675,544
30 Day Avg. Volume2,969,035
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)2.84
Price to Sales (P/S)1726.72
P/FCF Ratio-4.25
Enterprise Value/Market Cap0.25
Enterprise Value/Revenue16.08K
Enterprise Value/Gross Profit16.08K
Enterprise Value/Ebitda-1.13
Forecast
1Y Price Target
$3.13Price Target Upside184.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.23
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Development Momentum & Regulatory PathSurpassing the 50% enrollment milestone and a stated plan to complete enrollment in 2026 with a 2027 PMA target materially reduces regulatory timing uncertainty. A defined path to PMA strengthens the company’s strategic runway and clarifies commercialization planning for hospital acute-care markets.
Low Leverage And Balance-sheet FlexibilityZero reported debt and positive equity provide balance-sheet flexibility to fund clinical development and absorb episodic expenses. This low-leverage position reduces refinancing stress versus debt-heavy peers and supports continued R&D investment while management pursues milestone financing.
Operational Clinical Advantages (dosing Simplicity)Strong first-dose targeting and dosing stability lower operational complexity for acute-care settings, supporting site adoption and consistent treatment delivery. These characteristics can ease training burdens, improve trial efficiency, and strengthen the product's commercial fit in hospital workflows over the medium term.
Bears Say
Minimal Revenue And Sustained Net LossesNegligible recurring revenue and large, sustained net losses mean the company currently cannot self-fund operations from product sales. This durable cash deficit elevates dilution and refinancing risk, making long-term viability contingent on successful clinical outcomes or substantial external funding.
Reliance On Conditional Financing TranchesDependence on milestone‑contingent tranches creates structural funding risk: failure or delay in tranche triggers would force near-term alternative financing, potentially on dilutive terms, and could interrupt pivotal activities. This reliance materially affects the company’s execution certainty through PMA.
Enrollment Concentration & Timing VariabilityEnrollment concentrated in few sites and acknowledged 'ebbs and flows' create persistent timing risk for top-line data and regulatory milestones. Concentration increases operational vulnerability—any slowdown at key sites can delay LPO and the PMA timeline, affecting funding triggers and commercialization schedules.
Talphera News
TLPH FAQ
What was Talphera’s price range in the past 12 months?
Talphera lowest stock price was $0.38 and its highest was $1.57 in the past 12 months.
What is Talphera’s market cap?
Talphera’s market cap is $64.87M.
When is Talphera’s upcoming earnings report date?
Talphera’s upcoming earnings report date is Aug 19, 2026 which is in 40 days.
How were Talphera’s earnings last quarter?
Talphera released its earnings results on May 13, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.067 by $0.027.
Is Talphera overvalued?
According to Wall Street analysts Talphera’s price is currently Undervalued.
Does Talphera pay dividends?
Talphera does not currently pay dividends.
What is Talphera’s EPS estimate?
Talphera’s EPS estimate is -0.06.
How many shares outstanding does Talphera have?
Talphera has 51,899,647 shares outstanding.
What happened to Talphera’s price movement after its last earnings report?
Talphera reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.067. Following the earnings report the stock price went down -0.444%.
Which hedge fund is a major shareholder of Talphera?
Currently, no hedge funds are holding shares in TLPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Talphera Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.13 (184.09% Upside)
$3.13 (184.09% Upside)
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.75%
12-Months-Change
Fundamentals
Return on Equity
-92.98%
Trailing 12-Months
Asset Growth
101.10%
Trailing 12-Months
Company Description
Talphera
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being assessed under an investigational device exemption for its application in extracorporeal circuits. The company's development pipeline also features LTX-608, a potential anti-inflammatory and antiviral agent being explored for the treatment of numerous conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. Furthermore, Talphera is advancing Fedsyra, a pre-filled syringe containing ephedrine, and PFS-02, a pre-filled syringe containing phenylephrine. Established in 2005, the company was previously known as AcelRx Pharmaceuticals, Inc. It adopted the name Talphera, Inc. in January 2024 and maintains its corporate headquarters in San Mateo, California.
TLPH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical and operational momentum: enrollment has surpassed the 50% milestone, sites and KOLs reported favorable feedback on dosing simplicity and stability, and management expects a rapid top-line read in H2 2026 with a PMA plan for 2027. However, the company faces higher operating expenses and depends on two conditional financing tranches (~$16M) to fund the path to potential approval, with enrollment variability and financing contingency as primary risks. Overall, positive progress is balanced against execution and financing risk, but the highlights outweigh the lowlights.View all TLPH earnings summariesTLPH Stock 12 Month Forecast
Average Price Target
$3.13
▲(184.09% Upside)
Technical Analysis
Ownership Overview
6.01% Insiders
1.48% Mutual Funds
38.89% Other Institutional Investors
52.77% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---